Redx Pharma

Introducing zelasudil, our investigational next-generation selective ROCK2 inhibitor. For more information, please visit: https://lnkd.in/eRETdXTw

We look forward to attending the 8th Annual IPF Summit in Boston where Dr Elaine Kilgour, Head of Translational Science at Redx, will join an expert panel to discuss the topic: Comparatively Assess Novel & Disease-Specific Targets vs. Upstream Broad-Spectrum Targets to Unveil Untapped Opportunities for Enhanced IPF Therapeutics. As part of this panel workshop, Elaine will present Redx’s next-generation, highly selective ROCK2 inhibitor, zelasudil, which is currently progressing through a Phase 2a clinical study in patients with IPF. For more information, please click https://bit.ly/3WSurdX #IPFSummit #IPFcommunity #DrugDevelopment 

It is already two week since we were at #ESMOGI where we enjoyed meeting with peers old and new to discuss the latest advancements and data in GI targeted oncology. We were delighted to announce the Phase 2 data from our porcupine inhibitor, zamaporvint at the conference joined by Professor John Bridgewater and Dr. Ian Chau. Data from all patient cohorts of the PORCUPINE and PORCUPINE2 trials were presented and notably showed that zamaporvint in combination with anti-PD-1 in genetically-selected MSS mCRC patients led to partial responses being observed in ~30% patients, potentially higher than current standard of care, and in a setting where anti-PD-1 therapy alone is not effective.   Copies of both posters presented are now available on our website here: https://lnkd.in/gjpPKtnR #oncology #drugdevelopment #precisionmedicine

We are delighted to have presented the Phase 2 data from our Porcupine inhibitor, zamaporvint at #ESMOGI this week. Data from all patient cohorts of the PORCUPINE and PORCUPINE2 trials were presented which showed that zamaporvint in combination with anti-PD-1 in genetically-selected MSS mCRC patients led to partial responses being observed in ~30% patients, potentially higher than current standard of care, and in a setting where anti-PD-1 therapy alone is not effective. This data supports the genetic selection of patients in hard-to-treat GI cancers and further clinical development in this subgroup in combination with anti-PD-1 and with other rational zamaporvint combination opportunities to enhance patient benefit, such as with early line chemotherapies in wider GI cancer patient populations. For more information click https://bit.ly/3xCFrn4

📣 New job opportunity – Head of Regulatory   We are seeking an experienced regulatory affairs professional to join our team as Head of Regulatory and lead our regulatory strategy and operations. This newly established role will be responsible for ensuring that our products meet all regulatory requirements and facilitate timely product approvals. As a key member of the clinical leadership team, the ideal candidate will have extensive knowledge of global regulatory guidelines and a strong track record in regulatory submissions and compliance.  We are open to candidates from across the UK, Europe and US East Coast.   Redx Pharma Ltd is a dynamic small biotech company focused on innovative solutions in Fibrosis and Oncology. We are dedicated to advancing science and developing ground-breaking therapies to address unmet medical needs, with three wholly-owned assets currently in clinical development and an exciting development pipeline of potential new drug candidates.   If you are interested in learning more about this opportunity and potentially joining our world-class, innovative team, please contact: [email protected] Our Values:

We are delighted that Kirsty Houslay, Principal Scientist at Redx, will be presenting at the Extracellular Matrix Pharmacology Congress in Copenhagen tomorrow. #ECM2024 provides an opportunity for experts in the field of drug development in fibrosis to share knowledge and advancements in research for potential new treatments for fibrotic diseases and we look forward to discussing our GI-targeted pan-ROCK inhibitor, RXC008, currently in Phase 1 development for the treatment of fibrostenotic Crohn’s disease. For more information click: https://bit.ly/3z60rDg

Shares in Redx Pharma (“Redx”) (https://lnkd.in/ecPbsk48) have been admitted to trade on JP Jenkins share dealing platform.   Redx (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer.   JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).   Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.   The indicative pricing for the ordinary shares (ISIN: GB00BSNB6S51), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/)   Peter Collum, Chief Financial Officer, Redx Pharma said “We are pleased to be able to offer our shareholders the ability to continue trading Redx shares on the JP Jenkins platform as a private company following the delisting from AIM. The JP Jenkins platform allows buying and selling of shares through a structured secondary market using brokers in the same manner as trading a listed security. This will allow us to focus on the execution of our corporate strategy, driving forward our pipeline of differentiated, novel drug candidates and ultimately delivering shareholder returns.” Veronika Oswald, Commercial Director of JP Jenkins said: “Redx’s move from AIM to the JP Jenkins venue represents a significant step forward in our journey towards accessibility and liquidity for their investors. This transition underscores our commitment to fostering a dynamic and thriving investment environment. We're thrilled to embark on this new chapter with Redx, confident in the opportunities it will unlock for both companies. See full article here: https://lnkd.in/dXmWaYwG

We are excited to attend #BIOEuropeSpring next week where we look forward to discussing a number of potential future partnership opportunities. If you would like to meet with us, please request via the partneringONE platform. #pharmaceuticals #lifescience #oncology #precisionmedicine #innovation

We are delighted to be in Boston this week for the #TDCowenHealthCare conference. Our team will present tomorrow morning with the option to join a live webcast of the presentation available here: https://lnkd.in/ev4-6PgY

We are excited to confirm that the first participant has been dosed in the Phase 1 healthy volunteer study for our GI-targeted pan-ROCK inhibitor being developed as a potential treatment for fibrostenotic Crohn’s disease. Fibrostenosis affects approximately 50% of Crohn’s disease patients. Currently there are no approved therapeutic treatments, leaving invasive surgical interventions as the only option for many patients.  For more information click here: https://bit.ly/49VbBYJ